Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
324.17B
Market cap324.17B
Price-Earnings ratio
23.99
Price-Earnings ratio23.99
Dividend yield
1.93%
Dividend yield1.93%
Average volume
1.94M
Average volume1.94M
High today
$160.93
High today$160.93
Low today
$150.06
Low today$150.06
Open price
$159.90
Open price$159.90
Volume
1.29M
Volume1.29M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

The Wall Street Journal 2d
Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Shares of Novartis fell in after-hours trading on Friday. Florence Lo / Reuters A highly anticipated cholesterol drug from Novartis NOVN -1.33 %decrease; down...

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
TipRanks 2d
Novartis Pelacarsen Fails to Cut Cardiovascular Events in Key Phase III Lp(a) Trial

Novartis ( (NVS) ) has provided an announcement. On September 4, 2026, Novartis reported topline Phase III results from its Lp(a)HORIZON trial evaluating pelac...

The Wall Street Journal 2d
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Shares of Novartis declined in after-hours trading on Friday. Fabrice Coffrini / Agence France-Presse / Getty Images Novartis NOVN -1.33 %decrease; down pointi...

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Analyst ratings

41%

of 29 ratings
Buy
41.4%
Hold
41.4%
Sell
17.2%

More NVS News

Investor's Business Daily 2d
Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Technology Novartis, Ionis Tumble On Surprise Flop For Heart Drug Licensing Novartis (NVS) said late Friday its Ionis Pharmaceuticals (IONS)-partnered Lp(a) blo...

Novartis, Ionis Tumble On Surprise Flop For Heart Drug
TipRanks 2d
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did no...

24/7 Wall St. 3d
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One

Investing This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One Novartis just committed billions not to discover a new drug but to ch...

This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One
TipRanks 4d
H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

H.C. Wainwright reiterates a Buy rating on Halozyme (HALO) with a $115 price target after Novartis (NVS) signed an option and license agreement with Alteogen co...

TipRanks 4d
Alteogen enters option, license agreement with Novartis

Alteogen announced that it has entered into an option and license agreement with Novartis (NVS) for the development and commercialization of subcutaneous, SC, p...

TipRanks 5d
Novartis Maintained at Buy as Strong Remibrutinib Phase 3 Data Support RMS Opportunity; $135 Price Target Unchanged

Analyst Thibault Boutherin of Morgan Stanley maintained a Buy rating on Novartis AG, retaining the price target of CHF135.00. Thibault Boutherin has given his B...

Benzinga 5d
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Novartis AG (NYSE:NVS) stock climbed Tuesday after the Swiss drugmaker reported positive Phase 3 results for remibrutinib in relapsing multiple sclerosis. Remi...

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.